We are live on ! Find out more
KAM

Kazazian Asset Management Portfolio holdings

AUM $91.5M
1-Year Est. Return 35.36%
This Fund
S&P 500
This Quarter Est. Return
+2.51%
1 Year Est. Return
+35.36%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$107M
AUM Growth
-$2.31M
Cap. Flow
-$3.95M
Cap. Flow %
-3.69%
Top 10 Hldgs %
50.35%
Holding
99
New
11
Increased
15
Reduced
18
Closed
5

Top Buys

Rank Stock Value
1
DBRG icon
DigitalBridge
DBRG
+$1.53M
2
CLVS
Clovis Oncology, Inc.
CLVS
+$1.3M
3
PZZA icon
Papa John's
PZZA
+$1.27M
4
BIDU icon
Baidu
BIDU
+$893K
5
MLPA icon
Global X MLP ETF
MLPA
+$776K

Top Sells

Rank Stock Value
1
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$6.33M
2
BIIB icon
Biogen
BIIB
+$3.41M
3
EEM icon
iShares MSCI Emerging Markets ETF
EEM
+$612K
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$482K
5
NS
NuStar Energy L.P.
NS
+$450K

Sector Composition

Rank Sector Weight
1 Healthcare 31.8%
2 Financials 12.85%
3 Consumer Discretionary 11.11%
4 Communication Services 8.2%
5 Technology 5.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TSRO
51
DELISTED
TESARO, Inc.
TSRO
$391K 0.37%
10,024
– –
PXD
52
DELISTED
Pioneer Natural Resource Co.
PXD
$373K 0.35%
2,144
– –
LJPC
53
DELISTED
La Jolla Pharmaceutical Company
LJPC
$364K 0.34%
18,076
+3,133
+21% +$81.9K
APA icon
54
APA Corp
APA
$13.2B
$362K 0.34%
7,593
– –
NTLA icon
55
Intellia Therapeutics
NTLA
$1.67B
$359K 0.34%
12,530
– –
PYPL icon
56
PayPal
PYPL
$50.5B
$351K 0.33%
+4,000
New +$352K
PTLA
57
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$350K 0.33%
13,155
-6,264
-32% -$205K
PE
58
DELISTED
PARSLEY ENERGY INC
PE
$348K 0.33%
11,881
– –
ECYT
59
DELISTED
Endocyte, Inc. Common Stock
ECYT
$334K 0.31%
18,794
-6,264
-25% -$108K
VKTX icon
60
Viking Therapeutics
VKTX
$4B
$327K 0.31%
+18,792
New +$224K
ARNA
61
DELISTED
Arena Pharmaceuticals Inc
ARNA
$322K 0.3%
+7,000
New +$284K
CTRA
62
DELISTED
Coterra Energy
CTRA
$320K 0.3%
14,205
– –
UTHR icon
63
United Therapeutics
UTHR
$23.1B
$320K 0.3%
2,506
– –
ICPT
64
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$317K 0.3%
2,506
-2,506
-50% -$265K
GBT
65
DELISTED
Global Blood Therapeutics, Inc.
GBT
$310K 0.29%
8,146
-3,132
-28% -$139K
PTEN icon
66
Patterson-UTI
PTEN
$3.76B
$306K 0.29%
17,867
– –
AAMC
67
DELISTED
Altisource Asset Management Corp
AAMC
$300K 0.28%
8,529
– –
KPTI icon
68
Karyopharm Therapeutics
KPTI
$48M
$299K 0.28%
1,169
-209
-15% -$57.8K
ACOR
69
DELISTED
Acorda Therapeutics
ACOR
$284K 0.27%
120
– –
ARRY
70
DELISTED
Array Biopharma Inc
ARRY
$284K 0.27%
18,713
– –
NBIS
71
Nebius Group N.V.
NBIS
$47.7B
$277K 0.26%
8,413
– –
DCPH
72
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$271K 0.25%
+7,000
New +$259K
MDGL icon
73
Madrigal Pharmaceuticals
MDGL
$11.8B
$268K 0.25%
+1,253
New +$314K
VTRS icon
74
Viatris
VTRS
$18.9B
$256K 0.24%
+7,000
New +$263K
GM.WS.B
75
DELISTED
General Motors Company
GM.WS.B
$250K 0.23%
15,161
– –
1 2
3
4

Similar funds

MRP
Measured Risk Portfolios San Diego, California $91.4M AUM 0.88% 1-Year Est. Return
ITG
Index Technologies Group New York $91.8M AUM
MA
Marquette Associates Chicago, Illinois $91.9M AUM 13.47% 1-Year Est. Return
AW
Aspirean Wealth Mill Valley, California $92.1M AUM
SPCM
Spruce Point Capital Management New York $90.9M AUM
ML
MLP3 LLC Linwood, New Jersey $90.7M AUM
ICM
Incision Capital Management San Francisco, California $90.6M AUM
ACMC
Anchor Capital Management Company Raleigh, North Carolina $92.7M AUM 19.36% 1-Year Est. Return

Kazazian Asset Management's Q3 2018 Portfolio in Review

As of Q3 2018, Kazazian Asset Management held 99 positions worth $107M, down 2.1% from $109M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Kazazian Asset Management withdrew a net $3.95M in Q3 2018, closing 5 positions and reducing 18 holdings. Its most notable exit was Ultragenyx Pharmaceutical, an estimated $482K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 32% of assets, up from 30% a quarter earlier, followed by Financials and Consumer Discretionary.

Against the trend, Kazazian Asset Management opened a new position in Papa John's worth $1.41M.

  • Kazazian Asset Management's largest Q3 2018 buy was Papa John's: 27,500 shares worth $1.41M.
  • Kazazian Asset Management added most to DigitalBridge in Q3 2018, an estimated $1.53M increase.
  • Kazazian Asset Management's biggest Q3 2018 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $6.33M.
  • Kazazian Asset Management fully exited Ultragenyx Pharmaceutical in Q3 2018, selling an estimated $482K.
  • Kazazian Asset Management's ten largest holdings make up 50% of its $107M portfolio in Q3 2018.
  • Kazazian Asset Management opened 11 new positions and closed 5 in Q3 2018.
  • Kazazian Asset Management's portfolio value fell 2.1% quarter-over-quarter to $107M.

Based on Kazazian Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.